Relay Therapeutics Inc
Research Relay Therapeutics Inc (RLAY) on Bullrun: market cap USD 4.50B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRLAY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.50B
- Financial periodQ2 2026
- RevenueUSD 350.00K
- Net income-USD 83.71M
- Free cash flow-USD 54.11M
Valuation Snapshot
latest market cap is USD 4.50B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 15.36M | -USD 276.48M | -USD 235.87M | n/a | -1.61 | USD 84.02M | USD 32.46M | USD 567.06M |
| FY2024 | USD 10.01M | -USD 337.71M | -USD 251.13M | n/a | -2.36 | USD 124.29M | USD 48.50M | USD 777.79M |
| FY2023 | USD 25.55M | -USD 341.97M | -USD 304.44M | n/a | -2.79 | USD 143.74M | USD 53.47M | USD 752.00M |
| FY2022 | USD 1.38M | -USD 290.51M | -USD 238.55M | n/a | -2.59 | USD 151.79M | USD 22.02M | USD 950.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.50B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.47B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 691.15M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.36B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.81B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.32B | n/a | n/a | n/a |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Relay Therapeutics Inc's market cap?
Relay Therapeutics Inc's market capitalization is USD 4.50B.
What does Relay Therapeutics Inc do?
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases.